Long‐term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls

In this analysis, we examined the risk of secondary malignancies for tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) patients. We also collected data on specific risk factors for colorectal cancer. Ninety‐one patients with CML and 76 controls were included and in total 4 (4...

Descripción completa

Detalles Bibliográficos
Autores principales: Winkelmann, Nina, Schwarz, Michaela, Hildebrandt, Bert, Henke, Oliver, Bullinger, Lars, Na, Il‐Kang, Stintzing, Sebastian, le Coutre, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422034/
https://www.ncbi.nlm.nih.gov/pubmed/36051062
http://dx.doi.org/10.1002/jha2.502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422034/
https://www.ncbi.nlm.nih.gov/pubmed/36051062
http://dx.doi.org/10.1002/jha2.502

Ejemplares similares